PureTech Health (PRTC) Competitors

GBX 130.79 -1.41 (-1.07%)

As of 08:20 AM Eastern

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

Should you buy PureTech Health stock or one of its competitors? MarketBeat compares PureTech Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PureTech Health include Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), Ergomed (ERGO), Silence Therapeutics (SLN), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.

How does PureTech Health compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

PureTech Health has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	5.28	-£175.21M	-£15.10	N/A
PureTech Health	£4.66M	68.33	-£91.86M	-£46.00	N/A

Oxford Nanopore Technologies has a beta of 0.869, meaning that its stock price is 13% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.399308, meaning that its stock price is 40% more volatile than the broader market.

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 34.6% of PureTech Health shares are owned by institutional investors. 2.3% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 13.4% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies has a net margin of -64.85% compared to PureTech Health's net margin of -2,355.32%. Oxford Nanopore Technologies' return on equity of -29.43% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
PureTech Health	-2,355.32%	-31.98%	-13.39%

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, indicating a potential upside of 79.77%. PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 288.41%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts clearly believe PureTech Health is more favorable than Oxford Nanopore Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Oxford Nanopore Technologies had 4 more articles in the media than PureTech Health. MarketBeat recorded 5 mentions for Oxford Nanopore Technologies and 1 mentions for PureTech Health. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat PureTech Health's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford Nanopore Technologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PureTech Health beats Oxford Nanopore Technologies on 9 of the 16 factors compared between the two stocks.

How does PureTech Health compare to Oxford Biomedica?

Oxford Biomedica (LON:OXB) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

32.4% of Oxford Biomedica shares are owned by institutional investors. Comparatively, 34.6% of PureTech Health shares are owned by institutional investors. 25.9% of Oxford Biomedica shares are owned by company insiders. Comparatively, 13.4% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oxford Biomedica presently has a consensus price target of GBX 687, indicating a potential upside of 12.25%. PureTech Health has a consensus price target of GBX 508, indicating a potential upside of 288.41%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Oxford Biomedica has a net margin of -17.85% compared to PureTech Health's net margin of -2,355.32%. PureTech Health's return on equity of -31.98% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Biomedica	-17.85%	-48.56%	-12.67%
PureTech Health	-2,355.32%	-31.98%	-13.39%

In the previous week, PureTech Health had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Oxford Biomedica. Oxford Biomedica's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Oxford Biomedica	Neutral
PureTech Health	Neutral

PureTech Health has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Biomedica	£168.74M	4.39	-£143.51M	-£26.92	N/A
PureTech Health	£4.66M	68.33	-£91.86M	-£46.00	N/A

Oxford Biomedica has a beta of 1.095, indicating that its share price is 10% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.399308, indicating that its share price is 40% more volatile than the broader market.

Summary

PureTech Health beats Oxford Biomedica on 9 of the 15 factors compared between the two stocks.

How does PureTech Health compare to Ergomed?

Ergomed (LON:ERGO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Ergomed has a net margin of 9.87% compared to PureTech Health's net margin of -2,355.32%. Ergomed's return on equity of 18.08% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
PureTech Health	-2,355.32%	-31.98%	-13.39%

In the previous week, PureTech Health had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
PureTech Health	Neutral

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 288.41%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Ergomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ergomed	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Ergomed has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
PureTech Health	£4.66M	68.33	-£91.86M	-£46.00	N/A

71.1% of Ergomed shares are held by institutional investors. Comparatively, 34.6% of PureTech Health shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 13.4% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ergomed has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.399308, suggesting that its stock price is 40% more volatile than the broader market.

Summary

Ergomed beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does PureTech Health compare to Silence Therapeutics?

PureTech Health (LON:PRTC) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

In the previous week, PureTech Health had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Silence Therapeutics. PureTech Health's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score.

Company	Overall Sentiment
PureTech Health	Neutral
Silence Therapeutics	Neutral

Silence Therapeutics has a net margin of 0.00% compared to PureTech Health's net margin of -2,355.32%. Silence Therapeutics' return on equity of 0.00% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Silence Therapeutics	N/A	N/A	N/A

34.6% of PureTech Health shares are owned by institutional investors. 13.4% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Silence Therapeutics has higher revenue and earnings than PureTech Health. PureTech Health is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	68.33	-£91.86M	-£46.00	N/A
Silence Therapeutics	£11.35M	0.00	N/A	-£48.60	N/A

PureTech Health presently has a consensus target price of GBX 508, indicating a potential upside of 288.41%. Given PureTech Health's stronger consensus rating and higher probable upside, analysts plainly believe PureTech Health is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Silence Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

PureTech Health beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

How does PureTech Health compare to Avacta Group?

PureTech Health (LON:PRTC) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

34.6% of PureTech Health shares are held by institutional investors. Comparatively, 2.6% of Avacta Group shares are held by institutional investors. 13.4% of PureTech Health shares are held by insiders. Comparatively, 50.9% of Avacta Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Avacta Group has lower revenue, but higher earnings than PureTech Health. Avacta Group is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	£4.66M	68.33	-£91.86M	-£46.00	N/A
Avacta Group	£113K	3,411.33	-£30.08M	-£17.55	N/A

In the previous week, Avacta Group had 1 more articles in the media than PureTech Health. MarketBeat recorded 2 mentions for Avacta Group and 1 mentions for PureTech Health. Avacta Group's average media sentiment score of 0.34 beat PureTech Health's score of 0.00 indicating that Avacta Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avacta Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PureTech Health has a beta of 1.399308, indicating that its share price is 40% more volatile than the broader market. Comparatively, Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

PureTech Health has a net margin of -2,355.32% compared to Avacta Group's net margin of -30,398.21%. PureTech Health's return on equity of -31.98% beat Avacta Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PureTech Health	-2,355.32%	-31.98%	-13.39%
Avacta Group	-30,398.21%	-361.23%	-21.80%

PureTech Health presently has a consensus target price of GBX 508, suggesting a potential upside of 288.41%. Avacta Group has a consensus target price of GBX 99, suggesting a potential upside of 16.47%. Given PureTech Health's higher probable upside, analysts plainly believe PureTech Health is more favorable than Avacta Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Avacta Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PureTech Health beats Avacta Group on 8 of the 14 factors compared between the two stocks.

Get PureTech Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRTC vs. The Competition

Export

Metric	PureTech Health	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£318.36M	£461.91M	£6.25B	£2.77B
Dividend Yield	N/A	3.86%	2.80%	6.15%
P/E Ratio	-2.84	3.86	20.63	365.99
Price / Sales	68.33	7,543.17	552.00	87,939.46
Price / Cash	2.14	13.13	27.48	27.89
Price / Book	1.15	83.22	9.67	7.63
Net Income	-£91.86M	-£96.07M	£3.56B	£5.89B
7 Day Performance	1.23%	0.49%	-1.65%	0.58%
1 Month Performance	-1.22%	-0.17%	-2.61%	0.74%
1 Year Performance	2.18%	69.25%	30.05%	84.36%

PureTech Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRTC PureTech Health	1.48 of 5 stars	GBX 130.79 -1.1%	GBX 508 +288.4%	+1.1%	£318.36M	£4.66M	N/A	300
ONT Oxford Nanopore Technologies	2.6798 of 5 stars	GBX 113.51 -3.4%	GBX 218.60 +92.6%	-7.0%	£1.10B	£223.90M	N/A	1,281	Gap Down
OXB Oxford Biomedica	N/A	GBX 649 -1.5%	GBX 687 +5.9%	+101.7%	£784.76M	£168.74M	N/A	891
ERGO Ergomed	N/A	N/A	N/A	N/A	£701.00M	£152.09M	4,641.38	6
SLN Silence Therapeutics	N/A	N/A	N/A	N/A	£480.35M	£11.35M	N/A	100	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:PRTC) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Summary

How does PureTech Health compare to Oxford Biomedica?

Summary

How does PureTech Health compare to Ergomed?

Summary

How does PureTech Health compare to Silence Therapeutics?

Summary

How does PureTech Health compare to Avacta Group?

Summary

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PureTech Health (PRTC) Competitors

PRTC vs. ONT, OXB, ERGO, SLN, and AVCT

How does PureTech Health compare to Oxford Nanopore Technologies?

Which has higher valuation and earnings, ONT or PRTC?

Which has more risk & volatility, ONT or PRTC?

Do insiders and institutionals believe in ONT or PRTC?

Is ONT or PRTC more profitable?

Do analysts recommend ONT or PRTC?

Does the media prefer ONT or PRTC?

Summary

How does PureTech Health compare to Oxford Biomedica?

Do institutionals and insiders believe in OXB or PRTC?

Do analysts rate OXB or PRTC?

Is OXB or PRTC more profitable?

Does the media refer more to OXB or PRTC?

Which has preferable valuation and earnings, OXB or PRTC?

Which has more volatility & risk, OXB or PRTC?

Summary

How does PureTech Health compare to Ergomed?

Is ERGO or PRTC more profitable?

Does the media refer more to ERGO or PRTC?

Do analysts prefer ERGO or PRTC?

Which has stronger earnings and valuation, ERGO or PRTC?

Do institutionals & insiders believe in ERGO or PRTC?

Which has more volatility & risk, ERGO or PRTC?

Summary

How does PureTech Health compare to Silence Therapeutics?

Does the media favor PRTC or SLN?

Is PRTC or SLN more profitable?

Do institutionals and insiders believe in PRTC or SLN?

Which has better valuation & earnings, PRTC or SLN?

Do analysts recommend PRTC or SLN?

Summary

How does PureTech Health compare to Avacta Group?

Do institutionals and insiders have more ownership in PRTC or AVCT?

Which has stronger valuation and earnings, PRTC or AVCT?

Does the media favor PRTC or AVCT?

Which has more volatility and risk, PRTC or AVCT?

Is PRTC or AVCT more profitable?

Do analysts prefer PRTC or AVCT?

Summary

Media Sentiment Over Time

PRTC vs. The Competition

PureTech Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools